Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene Corp.

Division of Bristol-Myers Squibb Co.
www.celgene.com

Latest From Celgene Corp.

China-US Virus Showdown Creating Health Policy Uncertainties

China has stepped up its support for the World Health Organization just as the US is ratcheting up its criticism of both the global health body and China, as policy observers watch closely for any signs the tense bilateral relationship may spill over to the health sector.

China United States

Rise In Securities Class Action Filings In Life Sciences Sector

Last year proved to be another record period for securities class actions, with a 13% increase in cases filed compared with 2018, and a 24% increase in claims brought against life sciences companies compared with 2018, according to a report by Cornerstone Research: Securities Class Action Filings: 2019 Year In Review.

Business Strategies Commercial

ASCO 2020: BCMA CAR-T Race Heats Up Between Bristol And Janssen

The gap between potential approvals for Bristol’s ide-cel and Janssen’s JNJ-4528 has narrowed as both CAR-T therapies show high response rates in multiple myeloma – and as bispecific antibodies, including Janssen’s teclistamab, edge into the space.

ASCO ImmunoOncology

A BCMA Setback For Bristol And Bluebird With FDA Refuse-To-File Letter

The US FDA took issue with the CMC portion of the BLA for the BCMA-targeted therapy idecabtagene vicleucel for multiple myeloma. An approval is tied to a $9 CVR for Celgene shareholders. 

ImmunoOncology FDA
See All

Company Information

UsernamePublicRestriction

Register